● AI Equity Research · Healthcare

Abbott Laboratories (ABT)

AI stock analysis · Medical Devices · Last analyzed Aug 19, 2026

Compass Score

3.0/5

Call

Hold

Price

$112.68

AI Target

$119.40 +6.0%

AI Analyst Summary

Abbott Laboratories presents a compelling medium-term recovery thesis driven by accelerating revenue growth of 13% YoY and a normalization of earnings from COVID-era diagnostic distortions, with the forward P/E of 18.6x suggesting the market is already pricing in this inflection. The company's MedTech portfolio — anchored by continuous glucose monitoring (FreeStyle Libre), cardiac devices, and diagnostics — provides durable, diversified growth vectors. The primary risk is near-term earnings pressure, with trailing EPS down 47.5% YoY, which could weigh on sentiment if the recovery trajectory disappoints.

Catalysts

FreeStyle Libre CGM franchise: continued international expansion and U.S. share gains in the fast-growing Type 2 diabetes monitoring market could drive meaningful upside to consensus revenue estimates in upcoming quarters.
Earnings normalization: as the COVID-19 diagnostic revenue headwind rolls off the base comparison, EPS growth is expected to re-accelerate materially, potentially compressing the forward P/E well below 18x by end of fiscal year.
Pipeline execution: upcoming data readouts and product launches in electrophysiology and structural heart — including the Volt PFA system — could serve as near-term re-rating catalysts for the MedTech segment.

Fundamentals

Pe Trailing P/E 35.7x / Forward P/E 18.6x · 3.0/5

Trailing P/E of 35.7x is elevated relative to the healthcare sector median, but the forward P/E of 18.6x suggests meaningful earnings normalization ahead. Valuation is stretched on a trailing basis but more reasonable on a forward look.

Peg PEG 2.24 · 2.0/5

A PEG of 2.24 signals the stock is not cheap relative to its growth rate. While not egregiously expensive, this is above the 2.0 threshold where value becomes compelling, indicating modest overvaluation on a growth-adjusted basis.

Analyst Rating Buy consensus (1.6) · 4.0/5

Consensus rating of 1.6 maps to a strong Buy, with 21 Buy ratings and 6 Holds out of 25 analysts and zero Sell ratings. Broad institutional conviction with no bearish outliers is a constructive signal.

Earnings Trend EPS growth -47.5% YoY; Revenue growth +13.0% YoY · 2.0/5

The sharp -47.5% YoY EPS decline is a meaningful headwind, likely reflecting the post-COVID diagnostic revenue normalization and prior-year comparison effects. Revenue growth of 13% is encouraging, but until earnings normalize and re-accelerate, the earnings trend remains a concern.

Price Target Beat 4 of 4 quarters beat (last 4 quarters) · 3.0/5

Abbott has beaten EPS estimates in all 4 of the most recent quarters. However, with only 4 quarters of data available (rather than 8), the score is capped at 3 per methodology guidelines, though the perfect recent beat rate is encouraging.

Management Consistent executor with broad analyst confidence · 4.0/5

A 4-of-4 EPS beat rate over recent quarters, combined with zero Sell ratings from 25 analysts and strong revenue growth of 13%, reflects disciplined execution and capital allocation. Management appears to be navigating the post-pandemic normalization effectively.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.